Sudhakar Katakam

Array ( [id] => 17519303 [patent_doc_number] => 20220105151 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => ASARM TREATMENT FOR KIDNEY AND MINERALIZATION DISORDERS AND HYPERPHOSPHATEMIA [patent_app_type] => utility [patent_app_number] => 17/495556 [patent_app_country] => US [patent_app_date] => 2021-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12763 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17495556 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18836766 [patent_doc_number] => 11844823 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-19 [patent_title] => Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof [patent_app_type] => utility [patent_app_number] => 17/495137 [patent_app_country] => US [patent_app_date] => 2021-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 18131 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17495137 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17640643 [patent_doc_number] => 20220168381 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => FORMULATIONS CONTAINING A SOMATOSTATIN RECEPTOR AGONIST [patent_app_type] => utility [patent_app_number] => 17/491837 [patent_app_country] => US [patent_app_date] => 2021-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19591 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17491837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17807724 [patent_doc_number] => 20220259559 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY UPREGULATING JAG-1 [patent_app_type] => utility [patent_app_number] => 17/484658 [patent_app_country] => US [patent_app_date] => 2021-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59341 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17484658 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17792052 [patent_doc_number] => 20220251143 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => NON-HYDROLYZABLE NON-CLEAVABLE, STABLE LINKERS FOR PRECISION THERAPEUTICS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/476656 [patent_app_country] => US [patent_app_date] => 2021-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12096 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17476656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18604675 [patent_doc_number] => 11746125 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-05 [patent_title] => Biomimetic peptides derived from biological source and their uses in retarding aging and improving skin [patent_app_type] => utility [patent_app_number] => 17/475006 [patent_app_country] => US [patent_app_date] => 2021-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 18 [patent_no_of_words] => 5532 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17475006 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17334638 [patent_doc_number] => 20220000969 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => COMBINATIONS OF LYSOBACTIN AND AMINOGLYCOSIDES AGAINST DISEASES CAUSED BY GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA IN NON-HUMAN ANIMALS [patent_app_type] => utility [patent_app_number] => 17/466863 [patent_app_country] => US [patent_app_date] => 2021-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7049 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17466863 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20328428 [patent_doc_number] => 12458685 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-04 [patent_title] => Manufacture, formulation and dosing of apraglutide [patent_app_type] => utility [patent_app_number] => 17/462908 [patent_app_country] => US [patent_app_date] => 2021-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 34 [patent_no_of_words] => 36690 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17462908 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20328428 [patent_doc_number] => 12458685 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-04 [patent_title] => Manufacture, formulation and dosing of apraglutide [patent_app_type] => utility [patent_app_number] => 17/462908 [patent_app_country] => US [patent_app_date] => 2021-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 34 [patent_no_of_words] => 36690 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17462908 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20328428 [patent_doc_number] => 12458685 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-04 [patent_title] => Manufacture, formulation and dosing of apraglutide [patent_app_type] => utility [patent_app_number] => 17/462908 [patent_app_country] => US [patent_app_date] => 2021-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 34 [patent_no_of_words] => 36690 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17462908 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18427670 [patent_doc_number] => 11672871 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-13 [patent_title] => Peptide oligonucleotide conjugates [patent_app_type] => utility [patent_app_number] => 17/403403 [patent_app_country] => US [patent_app_date] => 2021-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 25 [patent_no_of_words] => 12372 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 345 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17403403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18182717 [patent_doc_number] => 20230043447 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 17/400387 [patent_app_country] => US [patent_app_date] => 2021-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47730 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 330 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17400387 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18582868 [patent_doc_number] => 20230265124 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => OXYTOCIN ANALOGUES AND METHODS FOR USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/006841 [patent_app_country] => US [patent_app_date] => 2021-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11825 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18006841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17958534 [patent_doc_number] => 20220339114 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => POLYPEPTIDE FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/383324 [patent_app_country] => US [patent_app_date] => 2021-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32261 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17383324 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18596023 [patent_doc_number] => 20230270814 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => COMBINATION PHARMACEUTICAL OF TEMOZOLOMIDE AND MUTANT IDH1 ENZYME INHIBITOR [patent_app_type] => utility [patent_app_number] => 18/016540 [patent_app_country] => US [patent_app_date] => 2021-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4344 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18016540 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18596023 [patent_doc_number] => 20230270814 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => COMBINATION PHARMACEUTICAL OF TEMOZOLOMIDE AND MUTANT IDH1 ENZYME INHIBITOR [patent_app_type] => utility [patent_app_number] => 18/016540 [patent_app_country] => US [patent_app_date] => 2021-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4344 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18016540 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17355422 [patent_doc_number] => 20220016218 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => LIPOPHILIC PEPTIDE PRODRUGS [patent_app_type] => utility [patent_app_number] => 17/371201 [patent_app_country] => US [patent_app_date] => 2021-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25396 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17371201 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17198677 [patent_doc_number] => 20210338771 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => AQUEOUS SUSPENSIONS OF CYCLOSPORIN [patent_app_type] => utility [patent_app_number] => 17/367261 [patent_app_country] => US [patent_app_date] => 2021-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46140 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17367261 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18649418 [patent_doc_number] => 20230295227 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => COMPOUNDS FOR USE IN DIAGNOSIS AND/OR MONITORING OF FIBROSIS [patent_app_type] => utility [patent_app_number] => 18/010904 [patent_app_country] => US [patent_app_date] => 2021-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11204 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18010904 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19226740 [patent_doc_number] => 12006373 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-06-11 [patent_title] => Identification and evaluation of novel peptide ligands specific to human CD3 epsilon [patent_app_type] => utility [patent_app_number] => 17/349825 [patent_app_country] => US [patent_app_date] => 2021-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 14924 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17349825 [rel_patent_id] =>[rel_patent_doc_number] =>)